SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Operating Expenses data on file, last reported at $9.3 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $9.3 million, up 52.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $31.5 million (up 12.65% YoY), and the FY2025 annual result was $28.3 million, down 10.28% from the prior year.
• Operating Expenses climbed to $9.3 million in Q1 2026 per SLS's latest filing, from $8.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $17.7 million in Q1 2022 and troughed at $6.1 million in Q1 2025.
• A 5-year average of $8.8 million and a median of $8.3 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 123.22% in 2022, then tumbled 37.14% in 2025.
• A 5-year view of Operating Expenses shows it stood at $9.4 million in 2022, then decreased by 13.43% to $8.2 million in 2023, then decreased by 15.4% to $6.9 million in 2024, then increased by 19.33% to $8.3 million in 2025, then rose by 12.08% to $9.3 million in 2026.
• Business Quant data shows SLS's Operating Expenses at $9.3 million in Q1 2026, $8.3 million in Q4 2025, and $7.1 million in Q3 2025.